venous thromboembolism
Cardiovascular · 2012–2019
5decisions
4medicines
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| enoxaparin Treatment of deep vein thrombosis (DVT) in patients requiring doses higher than currently available strengths. The new 120 mg and 150 mg formulations are… | Jul 2019 | Recommended | unclear |
| enoxaparin Prophylaxis or treatment of deep vein thrombosis (DVT) and venous thromboembolism (VTE) prophylaxis, particularly for extended prophylaxis in high-risk… | Mar 2019 | Recommended | input received |
| warfarin Prophylaxis and/or treatment of venous thrombosis and its extension and pulmonary embolism; prophylaxis and/or treatment of thromboembolic complications… | Nov 2016 | Not recommended | none received |
| apixaban Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), collectively referred to as venous thromboembolism (VTE); and prevention of recurrent… | Mar 2015 | Recommended | none received |
| rivaroxaban Prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF) who are at risk of developing stroke or systemic embolism… | Mar 2012 | Not recommended | unclear |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 4 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.